Skip to main content

Table 5 Baseline characteristics of study subjects

From: Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

Variable category Total (175, 100%) Reinfected group (26, 14.9%) Continuously eradicated group (149, 85.1%) p-value*
Gender (N = 175) (n = 26) (n = 149)  
  Male (104, 59.4%) (16, 61.5%) (88, 59.1%) 0.75
  Female (71, 40.6%) (10, 38.5%) (61, 40.9%)  
Age (years) (mean ± SD) (N = 175) (n = 26) (n = 149)  
(56.6 ± 9.4) (57.6 ± 9.4) (56.4 ± 9.5)
  20-29 (2, 1.1%) (0, 0.0%) (2, 1.3%) 0.47
  30-39 (4, 2.3%) (0, 0.0%) (4, 2.7%)  
  40-49 (34, 19.4%) (8, 30.8%) (26, 17.4%)  
  50-59 (61, 34.9%) (6, 23.1%) (55, 36.9%)  
  60-69 (62, 35.4%) (9, 34.6%) (53, 35.6%)  
  70-79 (11, 6.3%) (3, 11.5%) (8, 5.4%)  
  80-89 (1, 0.6%) (0, 0.0%) (1, 0.7%)  
Clinical diagnosis (N = 175) (n = 26) (n = 149)  
  Early gastric cancer (40, 22.9%) (7, 26.9%) (33, 22.1%) 0.74
  Dysplasia (19, 10.9%) (4, 15.4%) (15, 10.1%)  
  Peptic ulcer disease (34, 19.4%) (7, 26.9%) (27, 18.1%)  
  Chronic gastritis (82, 46.9%) (8, 30.8%) (74, 49.7%)  
Histological AG in either antrum or body (N = 116) (n = 20) (n = 96)  
  Yes (67, 57.8%) (14, 70.0%) (53, 55.2%) 0.14
  No (49, 42.2%) (6, 30.0%) (43, 44.8%)  
Histological IM in either antrum or body (N = 144) (n = 21) (n = 123)  
  Yes (84, 58.3%) (10, 47.6%) (74, 60.2%) 0.20
  No (60, 41.7%) (11, 52.4%) (49, 39.8%)  
Regimen (N = 175) (n = 26) (n = 149)  
  EBMT (59, 33.7%) (7, 26.9%) (52, 34.9%) 0.23
  MEA (116, 66.3%) (19, 73.1%) (97, 65.1%)  
  1. EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis; IM, intestinal metaplasia.
  2. All of early gastric cancer patients were cured by endoscopic submucosal dissection.
  3. * P-value for Log-rank test.